SLGL vs. AYTU, INDP, GLTO, VBIV, COCP, GLYC, KALA, NRBO, NERV, and TLPH
Should you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include Aytu BioPharma (AYTU), Indaptus Therapeutics (INDP), Galecto (GLTO), VBI Vaccines (VBIV), Cocrystal Pharma (COCP), GlycoMimetics (GLYC), KALA BIO (KALA), NeuroBo Pharmaceuticals (NRBO), Minerva Neurosciences (NERV), and Talphera (TLPH). These companies are all part of the "pharmaceutical preparations" industry.
Aytu BioPharma (NASDAQ:AYTU) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.
Aytu BioPharma has higher revenue and earnings than Sol-Gel Technologies. Aytu BioPharma is trading at a lower price-to-earnings ratio than Sol-Gel Technologies, indicating that it is currently the more affordable of the two stocks.
Aytu BioPharma has a beta of -1.23, suggesting that its stock price is 223% less volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500.
Aytu BioPharma has a net margin of -14.60% compared to Aytu BioPharma's net margin of -1,331.01%. Sol-Gel Technologies' return on equity of -31.31% beat Aytu BioPharma's return on equity.
Aytu BioPharma currently has a consensus price target of $5.00, indicating a potential upside of 70.07%. Sol-Gel Technologies has a consensus price target of $8.00, indicating a potential upside of 966.67%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Sol-Gel Technologies is more favorable than Aytu BioPharma.
In the previous week, Aytu BioPharma had 4 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 5 mentions for Aytu BioPharma and 1 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.72 beat Aytu BioPharma's score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the media.
33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 4.3% of Aytu BioPharma shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Aytu BioPharma received 108 more outperform votes than Sol-Gel Technologies when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 63.09% of users gave Sol-Gel Technologies an outperform vote.
Summary
Aytu BioPharma beats Sol-Gel Technologies on 10 of the 18 factors compared between the two stocks.
Get Sol-Gel Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sol-Gel Technologies Competitors List
Related Companies and Tools
